<DOC>
	<DOC>NCT02883595</DOC>
	<brief_summary>The purpose of this study is to determine whether thymosin alpha 1 is effective on improving monocyte function and has the desired pharmacologic activity for sepsis</brief_summary>
	<brief_title>Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis</brief_title>
	<detailed_description>Part 1: To observe the function of thymosin alpha 1 in sepsis patients via improving phagocytosis, bacteria eradication and antigen-presenting on monocyte Part 2: Pharmacokinetics of thymosin alpha 1 for sepsis</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<criteria>1. Written informed consent from the patients or their next of kin for patients unable to consent 2. Age â‰¥18 yrs 3. Presence of sepsis/ septic shock according to sepsis 3.0 1. Pregnant or lactation period. 2. Age &lt;18 yrs 3. Receiving immunosuppressive therapy such as cyclosporine, azathioprine or cancer chemotherapy within one month. 4. History of bone marrow, lung, liver, kidney, pancreas or small bowel transplantation; 5. Acute pancreatitis with no established source of infection. 6. Not expected to survive 28 days because of endstage diseases. 7. Participation in another clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>thymosin alpha 1; sepsis; monocyte; pharmacokinetics</keyword>
</DOC>